---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-26-000051"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:03:03.284308+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated

## Summary
- Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.
- FDA accepted IND for Descartes-08 in myositis; seamless adaptive Phase 2 TRITON trial expected to start 1H26.
- Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis initiated.
- Two Nature Medicine publications; Phase 2b MG data showed 55% median prednisone dose reduction at Month 12, no CRS or ICANS.
- Cash resources expected to fund operations including Phase 3 trial completion through mid-2027.

## SEC filing metadata
- accession: 0001453687-26-000051
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/0001453687-26-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/rnac-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-26-000051
- JSON: https://secwatch.observer/filing/0001453687-26-000051.json
- Plain text: https://secwatch.observer/filing/0001453687-26-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.